CN113993888B - 产生抗体的方法 - Google Patents

产生抗体的方法

Info

Publication number
CN113993888B
CN113993888B CN202080045482.6A CN202080045482A CN113993888B CN 113993888 B CN113993888 B CN 113993888B CN 202080045482 A CN202080045482 A CN 202080045482A CN 113993888 B CN113993888 B CN 113993888B
Authority
CN
China
Prior art keywords
codon
amino acid
antibody
nucleic acid
codons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045482.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113993888A (zh
Inventor
U·格普费特
S·克洛斯特曼
K·卢茨
S·西伯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN113993888A publication Critical patent/CN113993888A/zh
Application granted granted Critical
Publication of CN113993888B publication Critical patent/CN113993888B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080045482.6A 2019-06-28 2020-06-25 产生抗体的方法 Active CN113993888B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
EP19183171.8 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Publications (2)

Publication Number Publication Date
CN113993888A CN113993888A (zh) 2022-01-28
CN113993888B true CN113993888B (zh) 2026-01-06

Family

ID=67253661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045482.6A Active CN113993888B (zh) 2019-06-28 2020-06-25 产生抗体的方法

Country Status (11)

Country Link
US (1) US20220220500A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990484A1 (cg-RX-API-DMAC7.html)
JP (2) JP7511591B2 (cg-RX-API-DMAC7.html)
KR (1) KR102900433B1 (cg-RX-API-DMAC7.html)
CN (1) CN113993888B (cg-RX-API-DMAC7.html)
AU (1) AU2020304841B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025806A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143803A1 (cg-RX-API-DMAC7.html)
IL (1) IL289210A (cg-RX-API-DMAC7.html)
MX (1) MX2021015193A (cg-RX-API-DMAC7.html)
WO (1) WO2020260431A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156443A1 (en) * 2012-04-17 2013-10-24 F. Hoffmann-La Roche Ag Method for the expression of polypeptides using modified nucleic acids
WO2015128509A1 (en) * 2014-02-28 2015-09-03 Glenmark Pharmaceuticals S.A. Expression constructs and methods for selecting host cells expressing polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−23分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
WO2003070957A2 (en) 2002-02-20 2003-08-28 Novozymes A/S Plant polypeptide production
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
KR20090018799A (ko) 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
CA2657975A1 (en) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. A method for achieving improved polypeptide expression
KR101163295B1 (ko) * 2007-06-29 2012-07-05 에프. 호프만-라 로슈 아게 향상된 면역글로불린을 생산하는 중쇄 돌연변이체
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗IGF1R発現の増強のためのβGl−IGGイントロン
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
RU2612910C2 (ru) * 2011-12-21 2017-03-13 Ф. Хоффманн-Ля Рош Аг Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156443A1 (en) * 2012-04-17 2013-10-24 F. Hoffmann-La Roche Ag Method for the expression of polypeptides using modified nucleic acids
WO2015128509A1 (en) * 2014-02-28 2015-09-03 Glenmark Pharmaceuticals S.A. Expression constructs and methods for selecting host cells expressing polypeptides

Also Published As

Publication number Publication date
IL289210A (en) 2022-02-01
US20220220500A1 (en) 2022-07-14
AU2020304841B2 (en) 2024-08-15
MX2021015193A (es) 2022-01-18
EP3990484A1 (en) 2022-05-04
JP2023183417A (ja) 2023-12-27
KR20220024954A (ko) 2022-03-03
BR112021025806A2 (pt) 2022-02-08
CA3143803A1 (en) 2020-12-30
WO2020260431A1 (en) 2020-12-30
JP7835713B2 (ja) 2026-03-25
JP2022538178A (ja) 2022-08-31
JP7511591B2 (ja) 2024-07-05
CN113993888A (zh) 2022-01-28
AU2020304841A1 (en) 2021-12-23
KR102900433B1 (ko) 2025-12-15

Similar Documents

Publication Publication Date Title
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
CA2696809A1 (en) Method of increasing protein titres
US9708636B2 (en) Artificial introns
US10882910B2 (en) Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
EP3138917A1 (en) Method for the expression of polypeptides using modified nucleic acids
US20140248665A1 (en) Novel intron sequences
JP7835713B2 (ja) 抗体の製造方法
US9249201B2 (en) Heterologous intron within a signal peptide
HK40060841A (zh) 产生抗体的方法
TWI457441B (zh) 免疫球蛋白之製造
HK40060841B (en) Method for the production of an antibody
JP7650802B2 (ja) 抗ウサギcd19抗体および使用方法
JP2023501717A (ja) 新規の多重特異性抗体フォーマット
HK40058395A (en) Anti-rabbit cd19 antibodies and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060841

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant